SYS-CON MEDIA Authors: Xenia von Wedel, Peter Silva, Glenn Rossman, Ava Smith, Elizabeth White

News Feed Item

Cardiac Arrest Global Clinical Trials Review, H1, 2014

NEW YORK, Feb. 12, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cardiac Arrest Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p0869179/Cardiac-Arrest-Global-Clinical-Trials-Review-H1-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

Cardiac Arrest Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Cardiac Arrest Global Clinical Trials Review, H1, 2014" provides data on the Cardiac Arrest clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cardiac Arrest. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cardiac Arrest. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Cardiac Arrest 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Cardiac Arrest to Cardiovascular Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Cardiac Arrest to Cardiovascular Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Cardiac Arrest 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Cardiac Arrest Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Cardiac Arrest 33
Nov 07, 2012: Metformin Offers Cardio Benefits Over Sulfonylureas In Diabetes, Study Finds 33
Aug 22, 2012: NIH Launches Trial To Evaluate Anti-inflammatory Treatment For Preventing Heart Attacks, Strokes, And Cardiovascular Deaths 33
Aug 22, 2012: Brigham And Women's Hospital Researchers Initiate Major Cardiovascular Inflammation Reduction Trial Using Teva's Trexall 34
Mar 25, 2012: Infusion Of Abciximab Into Coronary Artery May Reduce Size Of Heart Damage After Heart Attack 35
Nov 13, 2011: Anti-Clotting Drug Lowers Risks In Acute Coronary Syndrome Treatment 36
Clinical Trial Profiles 37
Clinical Trial Overview of Top Companies 37
Janssen Global Services, LLC 37
Clinical Trial Overview of Janssen Global Services, LLC 37
Boston Scientific Corporation 38
Clinical Trial Overview of Boston Scientific Corporation 38
Biotronik SE & Co. KG 39
Clinical Trial Overview of Biotronik SE & Co. KG 39
PT Dexa Medica 40
Clinical Trial Overview of PT Dexa Medica 40
Johnson & Johnson 41
Clinical Trial Overview of Johnson & Johnson 41
Janssen-Cilag A.G. 42
Clinical Trial Overview of Janssen-Cilag A.G. 42
C. H. Boehringer Sohn AG & Co. KG 43
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 43
Clinical Trial Overview of Top Institutes / Government 44
Ottawa Hospital Research Institute 44
Clinical Trial Overview of Ottawa Hospital Research Institute 44
University of Washington 45
Clinical Trial Overview of University of Washington 45
National Heart, Lung, and Blood Institute 46
Clinical Trial Overview of National Heart, Lung, and Blood Institute 46
Kyoto University 47
Clinical Trial Overview of Kyoto University 47
Medical University of Vienna 48
Clinical Trial Overview of Medical University of Vienna 48
University of Pennsylvania 49
Clinical Trial Overview of University of Pennsylvania 49
Sunnybrook Health Sciences Centre 50
Clinical Trial Overview of Sunnybrook Health Sciences Centre 50
Assistance Publique - Hopitaux de Paris 51
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 51
University Hospital Basel 52
Clinical Trial Overview of University Hospital Basel 52
National Taiwan University Hospital 53
Clinical Trial Overview of National Taiwan University Hospital 53
Five Key Clinical Profiles 54
Appendix 74
Abbreviations 74
Definitions 74
Research Methodology 76
Secondary Research 76
About GlobalData 77
Contact Us 77
Disclaimer 77
Source 78

List of Tables

Cardiac Arrest Therapeutics, Global, Clinical Trials by Region, 2014* 7
Cardiac Arrest Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Cardiac Arrest Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Cardiac Arrest Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Cardiac Arrest Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Cardiac Arrest Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Cardiac Arrest Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Cardiac Arrest Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Cardiac Arrest to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Cardiac Arrest Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Cardiac Arrest Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Cardiac Arrest to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Cardiac Arrest Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Cardiac Arrest Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Cardiac Arrest Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Cardiac Arrest Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Cardiac Arrest Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Cardiac Arrest Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Cardiac Arrest Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Cardiac Arrest Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Cardiac Arrest Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Cardiac Arrest Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Cardiac Arrest Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Cardiac Arrest Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Cardiac Arrest Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Global Services, LLC, 2014* 37
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by Boston Scientific Corporation, 2014* 38
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by Biotronik SE & Co. KG, 2014* 39
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by PT Dexa Medica, 2014* 40
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014* 41
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen-Cilag A.G., 2014* 42
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 43
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by Ottawa Hospital Research Institute, 2014* 44
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 45
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 46
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by Kyoto University, 2014* 47
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2014* 48
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pennsylvania, 2014* 49
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by Sunnybrook Health Sciences Centre, 2014* 50
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 51
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Basel, 2014* 52
Cardiac Arrest Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 53

List of Figures

Cardiac Arrest Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Cardiac Arrest Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Cardiac Arrest Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Cardiac Arrest Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Cardiac Arrest Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Cardiac Arrest Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Cardiac Arrest Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Cardiac Arrest to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Cardiac Arrest Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Cardiac Arrest Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Cardiac Arrest to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Cardiac Arrest Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Cardiac Arrest Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Cardiac Arrest Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Cardiac Arrest Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Cardiac Arrest Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Cardiac Arrest Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Cardiac Arrest Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Cardiac Arrest Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Cardiac Arrest Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Cardiac Arrest Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 76

To order this report: Cardiac Arrest Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p0869179/Cardiac-Arrest-Global-Clinical-Trials-Review-H1-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
We are all here because we are sold on the transformative promise of The Cloud. But what good is all of this ephemeral, on-demand infrastructure if your usage doesn't actually improve the agility and speed of your business? How must Operations adapt in order to avoid stifling your Cloud initiative? In his session at DevOps Summit, Damon Edwards, co-founder and managing partner of the DTO Solutions, will highlight the successful organizational, process, and tooling patterns of high-performing c...
Software-driven innovation is becoming a primary approach to how businesses create and deliver new value to customers. A survey of 400 business and IT executives by the IBM Institute for Business Value showed businesses that are more effective at software delivery are also more profitable than their peers nearly 70 percent of the time (1). DevOps provides a way for businesses to remain competitive, applying lean and agile principles to software development to speed the delivery of software that ...
The definition of IoT is not new, in fact it’s been around for over a decade. What has changed is the public's awareness that the technology we use on a daily basis has caught up on the vision of an always on, always connected world. If you look into the details of what comprises the IoT, you’ll see that it includes everything from cloud computing, Big Data analytics, “Things,” Web communication, applications, network, storage, etc. It is essentially including everything connected online from ha...
Docker offers a new, lightweight approach to application portability. Applications are shipped using a common container format and managed with a high-level API. Their processes run within isolated namespaces that abstract the operating environment independently of the distribution, versions, network setup, and other details of this environment. This "containerization" has often been nicknamed "the new virtualization." But containers are more than lightweight virtual machines. Beyond their small...
The move in recent years to cloud computing services and architectures has added significant pace to the application development and deployment environment. When enterprise IT can spin up large computing instances in just minutes, developers can also design and deploy in small time frames that were unimaginable a few years ago. The consequent move toward lean, agile, and fast development leads to the need for the development and operations sides to work very closely together. Thus, DevOps become...
Cloud Expo 2014 TV commercials will feature @ThingsExpo, which was launched in June, 2014 at New York City's Javits Center as the largest 'Internet of Things' event in the world.

ARMONK, N.Y., Nov. 20, 2014 /PRNewswire/ --  IBM (NYSE: IBM) today announced that it is bringing a greater level of control, security and flexibility to cloud-based application development and delivery with a single-tenant version of Bluemix, IBM's

An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
The major cloud platforms defy a simple, side-by-side analysis. Each of the major IaaS public-cloud platforms offers their own unique strengths and functionality. Options for on-site private cloud are diverse as well, and must be designed and deployed while taking existing legacy architecture and infrastructure into account. Then the reality is that most enterprises are embarking on a hybrid cloud strategy and programs. In this Power Panel at 15th Cloud Expo (http://www.CloudComputingExpo.com...
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at Internet of @ThingsExpo, James Kirkland, Chief Ar...
Leysin American School is an exclusive, private boarding school located in Leysin, Switzerland. Leysin selected an OpenStack-powered, private cloud as a service to manage multiple applications and provide development environments for students across the institution. Seeking to meet rigid data sovereignty and data integrity requirements while offering flexible, on-demand cloud resources to users, Leysin identified OpenStack as the clear choice to round out the school's cloud strategy. Additional...
Technology is enabling a new approach to collecting and using data. This approach, commonly referred to as the "Internet of Things" (IoT), enables businesses to use real-time data from all sorts of things including machines, devices and sensors to make better decisions, improve customer service, and lower the risk in the creation of new revenue opportunities. In his General Session at Internet of @ThingsExpo, Dave Wagstaff, Vice President and Chief Architect at BSQUARE Corporation, discuss the ...
The security devil is always in the details of the attack: the ones you've endured, the ones you prepare yourself to fend off, and the ones that, you fear, will catch you completely unaware and defenseless. The Internet of Things (IoT) is nothing if not an endless proliferation of details. It's the vision of a world in which continuous Internet connectivity and addressability is embedded into a growing range of human artifacts, into the natural world, and even into our smartphones, appliances, a...
SYS-CON Media announced today that Aruna Ravichandran, VP of Marketing, Application Performance Management and DevOps at CA Technologies, has joined DevOps Journal’s authors. DevOps Journal is focused on this critical enterprise IT topic in the world of cloud computing. DevOps Journal brings valuable information to DevOps professionals who are transforming the way enterprise IT is done. Aruna's inaugural article "Four Essential Cultural Hacks for DevOps Newbies" discusses how to demonstrate the...
"BSQUARE is in the business of selling software solutions for smart connected devices. It's obvious that IoT has moved from being a technology to being a fundamental part of business, and in the last 18 months people have said let's figure out how to do it and let's put some focus on it, " explained Dave Wagstaff, VP & Chief Architect, at BSQUARE Corporation, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.